Immune-Related Pancytopenia Induced by Anti-PD-1 Therapy – Interrupt or Continue Treatment – The Role of Immunohistochemical Examination

Immune-Related Pancytopenia Induced by Anti-PD-1 Therapy – Interrupt or Continue Treatment – The Role of Immunohistochemical Examination

Immune checkpoint inhibitors (ICIs), including anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) and anti-programmed death receptor-1/ligand-1 (anti-PD-1/anti-PD-L1) caused a breakthrough in oncology and significantly improved therapeutic outcomes in cancer patients. ICIs generate a specific react...

Full description

Bibliographic Details
Main Authors: Bożena Cybulska-Stopa, Andrzej Gruchała, Maciej Niemiec
Format: Article
Language:English
Published: Karger Publishers 2019-10-01
Series:Case Reports in Oncology
Subjects:
anti-pd-1
immunotherapy
immune related adverse events
melanoma
pancytopenia
pembrolizumab
toxicity
Online Access:https://www.karger.com/Article/FullText/504130

Internet

https://www.karger.com/Article/FullText/504130

Similar Items